HRGβ overexpression in a large percentage of invasive breast cancers, and its ability to reduce the in vitro efficacy of trastuzumab against BT-474 cells [39], emphasizes the need to effectively compete for ligand-dependent activation of ERBB3. This evidence concerns the gene ERBB3 and invasive breast carcinoma.